Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

polycystic kidney disease 4 News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A rare PKHD1 frameshift variant has been identified in a prenatally diagnosed case of autosomal recessive polycystic kidney disease (ARPKD) from a consanguineous family in Jordan. This discovery adds to the understanding of genetic factors contributing to ARPKD.

Research reveals that the fibrocystin C-terminal domain inhibits Src/STAT3 signaling, which is linked to cystogenesis in kidney epithelial cells. This discovery could provide insights into therapeutic strategies for kidney diseases.

Recent research highlights the importance of kidney biopsies in accurately diagnosing kidney conditions in diabetes patients. This study aims to reduce mislabeling and improve patient outcomes by providing clearer insights into kidney pathology.

Recent research highlights the use of cell-type-specific damage scores to track disease trajectories in kidney and liver diseases through single-cell and spatial transcriptomics. This innovative approach could enhance understanding of disease progression and inform future therapeutic strategies.

Boulevard Bio has launched with $65 million in funding from Deerfield Management to develop multi-specific antibody programs targeting autoimmune diseases. The New York-based biotech aims to improve treatment for kidney disease and enhance precision immunology.

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease - BioSpace

New advanced MRI methods have been developed for assessing children and young adults with autosomal recessive polycystic kidney disease (ARPKD). These techniques aim to enhance the design and execution of future multi-center clinical trials.

A new study explores how African-enriched GATM regulatory variants affect creatinine-derived estimated glomerular filtration rate. This research could have implications for understanding kidney function in diverse populations.

HR 9891 proposes a demonstration program aimed at sharing savings with plans that invest in preventing the progression of kidney disease to end-stage renal disease. The bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for further consideration.

A study compares preemptive living-donor kidney transplantation with incident hemodialysis in Japan, highlighting regional differences in outcomes. This research provides insights into transplantation practices in areas with limited deceased-donor options.

Bristol Myers is partnering with Nvidia to establish a large AI data center, joining other pharma companies in leveraging AI technology. Meanwhile, Novartis has made strides with its kidney drug, enhancing its competitive position.

A recent study highlights how oral microbiota influences the relationship between healthy dietary patterns and a reduced risk of advanced cardiovascular-kidney-metabolic syndrome. This research underscores the potential role of diet and microbiome interactions in managing complex health conditions.

Recent research highlights the role of renin cells in creating a neuro-endocrine microenvironment within the kidney arterial tree, impacting both health and disease states. This discovery may provide insights into kidney-related disorders and potential therapeutic targets.

A new study evaluates the relationship between age, sex, and d-amino acid-based estimation of glomerular filtration rate. This research could provide insights into kidney function assessment in diverse populations.

HR 9169 has been introduced to support research on polycystic kidney disease. The bill is currently referred to the House Committee on Energy and Commerce for further consideration.

A case report highlights the implications of a single APOL1 G2 allele combined with a protective N264K variant in a child with kidney disease. This study contributes to understanding genetic factors influencing kidney disease risk.

A recent study highlights a patient with both aortic dilation and polycystic kidney disease, providing insights into the potential connections between these conditions. This case may inform future research on the genetic and clinical implications of co-occurring rare diseases.

A longitudinal study reveals that inflammation plays a key role in linking heavy metal exposures to kidney function decline. This research highlights the need for further investigation into environmental factors affecting renal health.

A recent study highlights the high prevalence of occult nephropathies found in radical nephrectomy specimens, shedding light on previously unrecognized kidney conditions. This research underscores the need for further investigation into these silent burdens affecting patient outcomes.

Biogen acquires Apellis Pharmaceuticals for $5.6 billion, enhancing its portfolio with two approved medicines and bolstering its pipeline for kidney disease treatments currently in Phase 3 trials. This strategic move positions Biogen for future growth in the kidney disease market.

Not rare diseases news,news about your rare disease.